Eventide Asset Management’s Viking Therapeutics VKTX Stock Holding History

Eventide Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-255,407	Closed	-$6.17M	–	255
2025 Q1	$6.17M	Sell	255,407 -187,290	-42%	-$5.92M	0.12%	136
2024 Q4	$17.8M	Sell	442,697 -10,272	-2%	-$586K	0.32%	98
2024 Q3	$28.7M	Buy	452,969 +200,000	+79%	+$11.7M	0.49%	66
2024 Q2	$13.4M	Hold	252,969	–	–	0.23%	113
2024 Q1	$20.7M	Sell	252,969 -497,031	-66%	-$22.1M	0.33%	91
2023 Q4	$14M	Hold	750,000	–	–	0.23%	107
2023 Q3	$8.3M	Hold	750,000	–	–	0.15%	128
2023 Q2	$12.2M	Buy	+750,000	New	+$15.7M	0.21%	116
2019 Q2	–	Sell	-1,757,000	Closed	-$17.5M	–	127
2019 Q1	$17.5M	Hold	1,757,000	–	–	0.6%	63
2018 Q4	$13.4M	Buy	1,757,000 +967,000	+122%	+$11.6M	0.6%	58
2018 Q3	$13.8M	Buy	+790,000	New	+$9.4M	0.51%	65

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Eventide Asset Management's VKTX Position: Q2 2025 in Review

Eventide Asset Management sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 255,407 shares — an estimated $6.17M sold.

Eventide Asset Management first reported a position in VKTX in Q3 2018 and held it in 11 quarters. The position peaked at $28.7M in Q3 2024. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

Eventide Asset Management reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
Eventide Asset Management sold 255,407 Viking Therapeutics shares in Q2 2025, an estimated $6.17M.
Eventide Asset Management first reported a position in Viking Therapeutics in Q3 2018 and held it in 11 quarters.
Eventide Asset Management's Viking Therapeutics position peaked at $28.7M in Q3 2024.
391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Eventide Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.